Calcitonin Gene-Related Peptide Receptor Antagonist Market Report 2026

Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview

• Calcitonin Gene-Related Peptide Receptor Antagonist market size has reached to $2.3 billion in 2025 • Expected to grow to $3.85 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Rising Migraine Prevalence Fueling Growth Of The Market Due To Chronic Stress • Market Trend: AbbVie’s Approval Highlights Innovation In Migraine Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Calcitonin Gene-Related Peptide Receptor Antagonist Market?

Calcitonin gene-related peptide receptor antagonist refers to a class of drugs that block the action of CGRP, a molecule involved in transmitting pain and dilating blood vessels, to help prevent or treat migraines and cluster headaches. These antagonists are helpful as they provide targeted migraine relief with fewer side effects compared to traditional migraine therapies, improving patient outcomes and quality of life. The main types of calcitonin gene-related peptide receptor antagonists are small molecule antagonists, monoclonal antibodies, and peptide-based antagonists. Small molecule antagonists refer to small chemicals that block certain proteins in the body, such as the CGRP receptor, to help prevent or reduce migraine pain. The multiple drug types involved are zavegepant, ubrogepant, olcegepant, telcegepant, rimegepant, and other drug types. The various applications include migraine treatment, pain management, cardiovascular conditions, and bone disorders and catering to several end users, such as hospitals, clinics, homecare settings, and pharmaceutical companies.

What Is The Calcitonin Gene-Related Peptide Receptor Antagonist Market Growth Forecast?

The calcitonin gene-related peptide receptor antagonist market size is expected to see rapid growth in the next few years. It will grow to $3.85 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to development of novel small molecule antagonists, expansion of peptide-based cgrp therapies, rising homecare treatment adoption, increasing pharmaceutical investments in migraine therapies, growing patient preference for fewer side-effect medications. Major trends in the forecast period include rising prevalence of migraines and cluster headaches, increasing adoption of targeted cgrp therapies, growth in homecare and outpatient treatment settings, expansion of monoclonal antibody-based therapies, enhanced focus on patient-centric pain management.

Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Segmentation

1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists 2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types 3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders 4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies Subsegments: 1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists 2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab 3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists

What Is The Driver Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market?

The increasing prevalence of migraine is expected to propel the growth of the calcitonin gene-related peptide receptor antagonist market going forward. Migraine refers to an intense headache that can cause throbbing pain, often on one side of the head. The rising prevalence of migraine is largely driven by increasing exposure to chronic stress, which disrupts neurological pathways and raises the likelihood of frequent and severe migraine attacks. Calcitonin gene-related peptide receptor antagonist helps migraine by blocking CGRP, a protein that widens blood vessels and transmits pain signals during a migraine attack, thereby reducing headache pain and other symptoms. For instance, in December 2025, according to the according to the report published by the National Center for Biotechnology Information (NCBI), a division of the US-based National Library of Medicine (NLM), an estimated 2.9 billion people worldwide were affected by headache disorders in 2023, with migraine alone accounting for around 487.5 cases per 100,000 population. Therefore, the increasing prevalence of migraine is driving the growth of the calcitonin gene-related peptide receptor antagonist industry.

Key Players In The Global Calcitonin Gene-Related Peptide Receptor Antagonist Market

Major companies operating in the calcitonin gene-related peptide receptor antagonist market are AbbVie Inc, Novartis AG, Eli Lilly and Company, Amgen Inc, Alder BioPharmaceuticals Inc, Satsuma Pharmaceuticals Inc, Allergan plc

Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Trends and Insights

Major companies operating in the calcitonin gene-related peptide receptor antagonist market are focusing on approvals for innovative products, such as oral CGRP receptor antagonists to enhance migraine treatment efficacy, expanding therapeutic indications, and offering more convenient administration routes. Oral CGRP receptor antagonists refer to small-molecule medicines that block CGRP, a protein linked to migraine attacks, helping prevent migraines. For instance, in April 2023, AbbVie Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA (atogepant) is an oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist developed for the preventive treatment of migraine in adults, now approved for both episodic and chronic migraine in the United States. It works by blocking the activity of CGRP, a protein that is elevated during migraine attacks and plays a role in pain signaling and inflammation in the brain. QULIPTA is available in 10 mg, 30 mg, and 60 mg tablet strengths, with the 60 mg dose specifically evaluated for chronic migraine prevention.

What Are Latest Mergers And Acquisitions In The Calcitonin Gene-Related Peptide Receptor Antagonist Market?

In December 2023, Organon & Co., a US-based healthcare company, partnered with Eli Lilly and Company to distribute and promote Emgality and RAYVOW in Europe for the treatment of migraine. With this partnership, Organon & Co. and Eli Lilly and Company aim to expand the availability of integrated migraine treatment options across Europe, improve patient access by leveraging Organon’s established commercial network, and enhance long-term treatment reach through streamlined distribution and promotional efforts. Eli Lilly and Company is a US-based pharmaceutical manufacturer known for developing innovative therapies across neurology, endocrinology, oncology, and immunology.

Regional Insights

North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Calcitonin Gene-Related Peptide Receptor Antagonist Market?

The calcitonin gene-related peptide receptor antagonist market consists of sales of atogepant, orally disintegrating CGRP receptor, and intranasal CGRP receptor antagonist sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Calcitonin Gene-Related Peptide Receptor Antagonist Market Report 2026?

The calcitonin gene-related peptide receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide receptor antagonist industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.